From molecules to the mind — and everything in between.
Complete topics to track progress
Voltage-gated, ligand-gated, leak channels. Action potential fundamentals.
Depolarization, repolarization, refractory periods, propagation.
Synaptic cleft, vesicles, release, postsynaptic receptors.
Excitatory, inhibitory, receptor types, receptor subunits.
Astrocytes, oligodendrocytes, microglia, Schwann cells.
Lobes, sulci, gyri, ventricles, meninges.
Midbrain, pons, medulla. Cranial nerve nuclei.
CN I-XII. Exit zones, functions, clinical testing.
Spinocerebellum, vestibulocerebellum, cerebrocerebellum.
Direct pathway, indirect pathway, Parkinson's disease.
Hippocampus, amygdala, Papez circuit, emotion & memory.
Circle of Willis, MCA, ACA, PCA, stroke territories.
Mental status, CN I-XII, motor, sensory, coordination, reflexes.
UMN vs LMN, cortical, brainstem, spinal cord, peripheral nerve.
Common presentations, red flags, clinical reasoning.
Mechanisms, PK, drug selection, TDM, DRE. VPA, LEV, LTG, CBZ, PHT and more.
Focal vs generalized, 2025 updates, absence vs FIA, lateralizing signs.
JME, JAE, GTCA, GEFS+, SUDEP, ASM withdrawal.
MDS 2015 clinical diagnostic criteria, red flags, supportive criteria, exclusions.
Hereditary cSVD: NOTCH3, HTRA1, CTSA. GOM, temporal pole MRI, alopecia.
D1/D5 agonist for PD. ICD risk 1.2% vs 17-28% with D2/D3 agonists.
Prophylaxis comparison. Candesartan 70% continuation vs 33% topiramate.
Seizure vs epilepsy vs resolved; three diagnostic criteria; provoked vs unprovoked.
10-20 system, normal rhythms, epileptiform, activation procedures, NCSE criteria.
SCN1A-Dravet, KCNQ2, CDKL5, PCDH19, mTOR pathway, TSC, GLUT1, precision therapy.
3T epilepsy MRI, HS, FCD, DNET, ganglioglioma, PET, SISCOM, SPECT timing.
VPA 6-10% MCM, NEAD IQ deficit, LTG/LEV preferred, PK changes, NICE NG217.
ILAE 2017 three-level, four epilepsy types, six etiologies, ILAE 2022 syndromes.
Tap each card to reveal the answer
Tap each question to reveal the answer